Biogen is an established biopharmaceutical company focused on treatments for neurological diseases and rare diseases. Its declining multiple sclerosis franchise is its largest revenue generator and contributed 45% of total revenue in 2024. Biogen also generates significant revenue from its CD20 collaboration agreements with Roche (18% of total in 2024), which includes oncology drugs Rituxan and Gazyva and multiple sclerosis drug Ocrevus. Biogen's newer franchises include Spinraza (spinal muscular atrophy, with partner Ionis), Leqembi (Alzheimer's disease, collabroation revenue from its partner Eisai), Skyclarys (Friedreich's ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (amyotrophic lateral sclerosis, Ionis).
Click "Analyze" to generate stock analysis
BIIB Price Trend and Signals
BIIB Option Volumes & Open Interests (aggregated)
BIIB Put Call Ratios and IV (aggregated)
BIIB Financials
2026-03-13Somewhat Bearishprice_signal
Monthly low detected.
2026-02-25Somewhat Bearishmacd_signal
Dead cross above zero detected.
2026-02-06Somewhat Bullishprice_signal
Yearly high detected.
2026-01-30Bullishmacd_signal
Golden cross below zero detected.
2026-01-21Somewhat Bullishbottom_signal_v1
Potential bottom confirmed based on multi-timeframe lows.
2026-01-16Somewhat Bearishprice_signal
Monthly low detected.
2026-01-15Somewhat Bearishprice_signal
Monthly low detected.
2026-01-14Somewhat Bearishmacd_signal
Dead cross above zero detected.
2026-01-14Somewhat Bearishprice_signal
Monthly low detected.
2026-01-09Somewhat Bullishprice_signal
Yearly high detected.
2026-01-07Somewhat Bullishmacd_signal
Golden cross above zero detected.
2026-01-07Somewhat Bullishprice_signal
Yearly high detected.
2026-01-06Somewhat Bullishprice_signal
Yearly high detected.
2025-12-19Neutralvolume_signal
Abnormal volume detected compared to 5-day moving average.
2025-12-19Neutralvolume_signal
Abnormal volume detected compared to 10-day moving average.
2025-12-19Neutralvolume_signal
Abnormal volume detected compared to 20-day moving average.
2025-12-19Neutralvolume_signal
Abnormal volume detected compared to 3 mon moving average.
2025-07-22Somewhat Bullishbottom_signal_v1
Potential bottom confirmed based on multi-timeframe lows.
2025-06-25Somewhat Bullishbottom_signal_v1
Potential bottom confirmed based on multi-timeframe lows.
2025-04-14Somewhat Bullishbottom_signal_v1
Potential bottom confirmed based on multi-timeframe lows.
2025-03-26Somewhat Bullishbottom_signal_v1
Potential bottom confirmed based on multi-timeframe lows.
2025-02-21Somewhat Bullishbottom_signal_v1
Potential bottom confirmed based on multi-timeframe lows.
2025-01-22Somewhat Bullishbottom_signal_v1
Potential bottom confirmed based on multi-timeframe lows.
2024-12-23Somewhat Bullishbottom_signal_v1
Potential bottom confirmed based on multi-timeframe lows.